Table 3.

Best overall response by dose group

Pembrolizumab 2 mg/kg + utomilumab mg/kg
0.450.91.83.65Total
N5333923
CRa n (%)001 (33.3)01 (11.1)2 (8.7)
PRa n (%)2 (40)001 (33.3)1 (11.1)4 (17.4)
Stable disease, n (%)2 (40)2 (66.7)1 (33.3)2 (66.7)3 (33.3)10 (43.5)
Objective progression, n (%)1 (20)1 (33.3)1 (33.3)04 (44.4)7 (30.4)
Objective response rate, n (%)2 (40)01 (33.3)1 (33.3)2 (22.2)6 (26.1)
95% exact CIb5.3–85.30–70.80.8–90.60.8–90.62.8–60.010.2–48.4
  • aCRs were observed in patients with SCLC and RCC; PRs in patients with anaplastic thyroid carcinoma, NSCLC, RCC, and HNSCC.

  • bCalculated using the Clopper–Pearson method.